NAACCR Item #3941: NRAS Mutational Analysis
|Item #||Length||Source of Standard||Year Implemented||Version Implemented||Year Retired||Version Retired|
NAACCR XML: Tumor.nrasMutationalAnalysis
NRAS is a signaling intermediate in the growth receptor pathway. Certain NRAS mutations predict poor response to anti-EGFR therapy in patients with metastatic colorectal cancer.
NRAS mutational analysis is recommended in clinical guidelines for patients with metastatic colon cancer who are being considered for anti-EGFR therapy. It is a new data item for cases diagnosed 01/01/2021+.
|0||Normal NRAS negative; NRAS wild type Negative for (somatic) mutations, no alterations, no (somatic) mutations identified, not present, not detected|
|1||Abnormal (mutated)/detected in codon(s) 12, 13, and/or 61|
|2||Abnormal (mutated)/detected, codon(s) specified but not in codon(s) 12, 13, or 61|
|4||Abnormal (mutated), NOS, codon(s) not specified|
|7||Test ordered, results not in chart|
|8||Not applicable: Information not collected for this case If this information is required by your standard setter, use of code 8 may result in an edit error.|
|9||Not documented in medical record NRAS not assessed or unknown if assessed|
Each Site-Specific Data Item (SSDI) applies only to selected primary sites, histologies, and years of diagnosis. Depending on applicability and standard-setter requirements, SSDIs may be left blank.